Chin-Sheng Lin1, Wei-Shiang Lin1, Cheng-Li Lin2, Chia-Hung Kao3. 1. Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 2. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan. 3. Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan. Electronic address: d10040@mail.cmuh.org.tw.
Abstract
BACKGROUND: To investigate the effect of carvedilol on the incidence of cancer in a large population-based cohort study. METHODS: Data were obtained from the Taiwan National Health Insurance Research Database. The cohort study included 6771 patients who received long-term carvedilol treatment between 2000 and 2010 (carvedilol cohort) and 6771 matched controls (noncarvedilol cohort). A Cox proportional hazards model was used to evaluate the risk of cancer in the patients treated with carvedilol. RESULTS: With the mean follow-up period of 5.17 years and 4.93 years in the carvedilol and noncarvedilol cohorts, respectively, the patients in the carvedilol cohort had a 26% reduction of cancer risk compared with those in the noncarvedilol cohort (hazard ratio [HR]=0.74; 95% confidence interval [CI]=0.63-0.87; p<.001). The sex-specific carvedilol to noncarvedilol relative risk was lower for both women (HR=0.73; 95% CI=0.56-0.94) and men (HR=0.75; 95% CI=0.61-0.92). Moreover, stratified by cancer site, treatment with carvedilol in the carvedilol cohort resulted in significantly lower incidence of stomach and lung cancers than in the noncarvedilol cohort. CONCLUSION: This nationwide population-based cohort study demonstrated that long-term treatment with carvedilol is associated with reduced upper gastrointestinal tract and lung cancer risk, indicating that carvedilol could be a potential agent in these cancers prevention.
BACKGROUND: To investigate the effect of carvedilol on the incidence of cancer in a large population-based cohort study. METHODS: Data were obtained from the Taiwan National Health Insurance Research Database. The cohort study included 6771 patients who received long-term carvedilol treatment between 2000 and 2010 (carvedilol cohort) and 6771 matched controls (noncarvedilol cohort). A Cox proportional hazards model was used to evaluate the risk of cancer in the patients treated with carvedilol. RESULTS: With the mean follow-up period of 5.17 years and 4.93 years in the carvedilol and noncarvedilol cohorts, respectively, the patients in the carvedilol cohort had a 26% reduction of cancer risk compared with those in the noncarvedilol cohort (hazard ratio [HR]=0.74; 95% confidence interval [CI]=0.63-0.87; p<.001). The sex-specific carvedilol to noncarvedilol relative risk was lower for both women (HR=0.73; 95% CI=0.56-0.94) and men (HR=0.75; 95% CI=0.61-0.92). Moreover, stratified by cancer site, treatment with carvedilol in the carvedilol cohort resulted in significantly lower incidence of stomach and lung cancers than in the noncarvedilol cohort. CONCLUSION: This nationwide population-based cohort study demonstrated that long-term treatment with carvedilol is associated with reduced upper gastrointestinal tract and lung cancer risk, indicating that carvedilol could be a potential agent in these cancers prevention.
Authors: Md Abdullah Shamim; Steven Yeung; Ayaz Shahid; Mengbing Chen; Jeffrey Wang; Preshita Desai; Cyrus Parsa; Robert Orlando; Frank L Meyskens; Kristen M Kelly; Bradley T Andresen; Ying Huang Journal: Int J Pharm Date: 2021-11-15 Impact factor: 5.875
Authors: James Yarmolinsky; Virginia Díez-Obrero; Tom G Richardson; Marie Pigeyre; Jennifer Sjaarda; Guillaume Paré; Venexia M Walker; Emma E Vincent; Vanessa Y Tan; Mireia Obón-Santacana; Demetrius Albanes; Jochen Hampe; Andrea Gsur; Heather Hampel; Rish K Pai; Mark Jenkins; Steven Gallinger; Graham Casey; Wei Zheng; Christopher I Amos; George Davey Smith; Richard M Martin; Victor Moreno Journal: PLoS Med Date: 2022-02-03 Impact factor: 11.069
Authors: Sherry Liang; Md Abdullah Shamim; Ayaz Shahid; Mengbing Chen; Kristan H Cleveland; Cyrus Parsa; Robert Orlando; Bradley T Andresen; Ying Huang Journal: Cancer Prev Res (Phila) Date: 2021-03-01
Authors: Moran Amit; Hideaki Takahashi; Mihnea Paul Dragomir; Antje Lindemann; Frederico O Gleber-Netto; Curtis R Pickering; Simone Anfossi; Abdullah A Osman; Yu Cai; Rong Wang; Erik Knutsen; Masayoshi Shimizu; Cristina Ivan; Xiayu Rao; Jing Wang; Deborah A Silverman; Samantha Tam; Mei Zhao; Carlos Caulin; Assaf Zinger; Ennio Tasciotti; Patrick M Dougherty; Adel El-Naggar; George A Calin; Jeffrey N Myers Journal: Nature Date: 2020-02-12 Impact factor: 69.504